ArticleEClinicalMedicine2026

Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trial.

Sander W Tas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.